1L advanced, unresectable, or metastatic NSCLC
1L advanced, unresectable, or metastatic NSCLC
Maintenance in unresectable or metastatic MSS/mismatch repair proficient CRC
Maintenance in unresectable or metastatic MSS/mismatch repair proficient CRC
Advanced solid tumors
Advanced solid tumors
Advanced or metastatic solid tumors
Advanced or metastatic solid tumors
Resectable stage II/IIIA NSCLC
Resectable stage II/IIIA NSCLC
1L HER2+ BC and 1L HER2+ GC/GEJC
1L HER2+ BC and 1L HER2+ GC/GEJC
1L HER2+ advanced/metastatic GC/EC
1L HER2+ advanced/metastatic GC/EC
2L+ HER2+ BTC
2L+ HER2+ BTC
Advanced NSCLC after anti-PD-(L)1 therapy
Advanced NSCLC after anti-PD-(L)1 therapy
Advanced GC/GEJC/HCC
Advanced GC/GEJC/HCC
HCC post resection
HCC post resection
Advanced ESCC after anti-PD-(L)1 therapy
Advanced ESCC after anti-PD-(L)1 therapy
Advanced GC/GEJC, CRC, and NSCLC
Advanced GC/GEJC, CRC, and NSCLC
Advanced triple negative BC, EC, and CRC
Advanced triple negative BC, EC, and CRC
1L/2L GC/GEJC
1L/2L GC/GEJC
1L advanced ESCC
1L advanced ESCC
Resectable stage II or IIIA NSCLC
Resectable stage II or IIIA NSCLC
1L advanced nasopharyngeal cancer
1L advanced nasopharyngeal cancer
1L squamous NSCLC
1L squamous NSCLC
1L non-squamous NSCLC
1L non-squamous NSCLC
1L advanced UBC
1L advanced UBC
Resectable ESCC
Resectable ESCC
Localized ESCC
Localized ESCC
Select advanced solid tumors
Select advanced solid tumors
1L MSI-H or dMMR CRC
1L MSI-H or dMMR CRC
Previously treated advanced MSI-high or dMMR solid tumors
Previously treated advanced MSI-high or dMMR solid tumors
2L/3L maintenance platinum-sensitive OC
2L/3L maintenance platinum-sensitive OC
Advanced OC and TNBC
Advanced OC and TNBC
Previously untreated, stage III unresectable NSCLC
Previously untreated, stage III unresectable NSCLC
Previously untreated LS-SCLC
Previously untreated LS-SCLC
1L PD-L1 high advanced NSCLC
1L PD-L1 high advanced NSCLC
2L PD-L1+ advanced ESCC
2L PD-L1+ advanced ESCC
2L+ cervical cancer
2L+ cervical cancer
Advanced solid tumors with BRAF mutations
Advanced solid tumors with BRAF mutations
R/R DLBCL with CD79B
R/R DLBCL with CD79B
Previously treated B-cell malignancies
Previously treated B-cell malignancies
B-cell malignancies
B-cell malignancies
Bioavailability of zanubrutinib tablets vs capsules in healthy volunteers"
Bioavailability of zanubrutinib tablets vs capsules in healthy volunteers"
R/R multiple myeloma with t(11;14)
R/R multiple myeloma with t(11;14)
Myeloid malignancies
Myeloid malignancies